In summary, our large real‐world study demonstrated that cross‐lineage expression of the myeloid antigen CD13/CD33 in adult B‐ALL can predict the risk of MRD positivity and the presence of the BCR::ABL1/Ph chromosome but has no adverse effect on patient outcomes. This evidence concerns the gene BCR and acute lymphoblastic leukemia.